| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
Correspondence to: David S. Hui, MD, FCCP, Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong; e-mail: dschui{at}cuhk.edu.hk
Objective: A case-controlled study to assess the effects of nasal continuous positive airway pressure (CPAP) on platelet activation in patients with obstructive sleep apnea (OSAS) syndrome.
Methods: We recruited 65 patients with suspected OSAS for this study. Blood samples were taken with the patient in the supine position in the morning immediately after polysomnography, and 1 night and 3 months after the start of nasal CPAP therapy to measure an index of platelet activation (IPA+), which reflected both the quantity and quality of platelet activation. Significant OSAS was defined as an apnea-hypopnea index (AHI) of 
10 events per hour.
Results: There were 42 patients with significant OSAS and 23 control subjects with AHI < 10 events per hour. The mean (± SD) age for the OSAS patients was 48 ± 9 years, the mean body mass index was 30.7 ± 4.8, the mean AHI was 47 ± 25 events per hour, the mean arousal index (AI) was 37 ± 23 events per hour, and the mean minimum arterial oxygen saturation was 74 ± 11%. Following multiple linear regression analyses of the clinical and polysomnography parameters, AI was the independent factor that correlated best with the baseline IPA+ (ß-coefficient, 0.386; p = 0.006). Following nasal CPAP treatment with a mean objective CPAP compliance of 3.9 ± 1.9 h per night, there was a significant decrease in IPA+ from 15.1 ± 12.2 U (at baseline) to 12.2 ± 5.2 U (p < 0.001) and 9.8 ± 4.3 U (p = 0.005), respectively, after 1 night and 3 months, whereas no significant change was noted among the control subjects. Using univariate analysis of variance to compare the changes in IPA+ between the two groups at 3 months with adjustment for the baseline value, nasal CPAP reduced IPA+ by 5.63 (SE, 1.85), whereas IPA+ increased in control subjects by 1.33 (SE, 1.27) [least-squared mean difference between groups, 3.34; 95% confidence interval, 0.42 to 6.26; p = 0.026].
Conclusions: OSAS, through repeated episodes of arousals, may lead to platelet activation, which can be reduced by nasal CPAP therapy.
Key Words: continuous positive airway pressure • platelet activation • sleep-disordered breathing
This article has been cited by other articles:
|
|
 |
|
  R. von Kanel, J. S. Loredo, S. Ancoli-Israel, P. J. Mills, L. Natarajan, and J. E. Dimsdale Association Between Polysomnographic Measures of Disrupted Sleep and Prothrombotic Factors Chest, March 1, 2007; 131(3): 733 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. O'Brien, L. D. Serpero, R. Tauman, and D. Gozal Plasma adhesion molecules in children with sleep-disordered breathing. Chest, April 1, 2006; 129(4): 947 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Staats, P Stoll, D Zingler, J C Virchow, and M Lommatzsch Regulation of brain-derived neurotrophic factor (BDNF) during sleep apnoea treatment Thorax, August 1, 2005; 60(8): 688 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dunleavy, M. Dooley, D. Cox, and A. Bradford Chronic intermittent asphyxia increases platelet reactivity in rats Exp Physiol, May 1, 2005; 90(3): 411 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Olson, E. J. Olson, and V. K. Somers Obstructive Sleep Apnea and Platelet Activation: Another Potential Link Between Sleep-Disordered Breathing and Cardiovascular Disease Chest, August 1, 2004; 126(2): 339 - 341. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
